Tradegate
09.04.26 | 20:24
2,080 Euro
+2,97 % +0,060
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,990 | 2,040 | 13:04 | |
| 1,970 | 2,060 | 10.04. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | H.C. Wainwright reiterates NovaBridge stock rating on drug durability | 1 | Investing.com | ||
| Di | I-Mab Biopharma GAAP EPS of -$0.48 | 2 | Seeking Alpha | ||
| Di | NovaBridge Biosciences: NovaBridge Reports Full Year 2025 Financial Results and Provides Business Update | 831 | GlobeNewswire (Europe) | Successful transformation to global biotech platform with two mid-stage potential best-in-class/first-in-class programs, givastomig and VIS-101, with compelling proof-of-concept dataGivastomig, a... ► Artikel lesen | |
| Di | NovaBridge Biosciences - 6-K, Report of foreign issuer | - | SEC Filings | ||
| Di | NovaBridge Biosciences - 20-F, Annual and transition report of foreign private issuers | - | SEC Filings | ||
| 16.03. | H.C. Wainwright reiterates NovaBridge stock rating on FDA feedback | 4 | Investing.com | ||
| 16.03. | NovaBridge Biosciences - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| NOVABRIDGE BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 09.03. | Mid-Cap NovaBridge Biosciences Stock Jumps Fueled By Positive Study Data In Eye Disease | 2 | Benzinga.com | ||
| 09.03. | NovaBridge Reports Positive Topline Results From Phase 2a Study Of VIS-101 | 4 | RTTNews | ||
| 09.03. | NovaBridge Biosciences: NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study | 401 | GlobeNewswire (Europe) | VIS-101, purpose-designed to be best-in-class for retinal vascular diseases, is a tetravalent, dual VEGF-A X ANG-2 inhibitorTopline Phase 2a data show VIS-101 provides rapid, robust and durable treatment... ► Artikel lesen | |
| 03.03. | NovaBridge Biosciences - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 03.03. | NovaBridge Biosciences: NovaBridge to Host Business Update Call to Review Phase 2a Data for VIS-101 in Wet AMD on Monday, March 9, 2026 | 3 | GlobeNewswire (USA) | ||
| 19.02. | NovaBridge Biosciences: NovaBridge Appoints Biotech Leader, Emmett T. Cunningham, Jr, MD, PhD, MPH, as Vice Chairman of the Board to Further Accelerate Global Biotech Platform | 1.398 | GlobeNewswire (Europe) | Appointment is a positive endorsement of NovaBridge's unique hub-and-spoke model and focus on creating shareholder value by accelerating the development of transformative medicines for patients around... ► Artikel lesen | |
| 19.02. | NovaBridge Biosciences - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 17.02. | NovaBridge enrolls first patient in phase 2 gastric cancer study | 1 | Investing.com | ||
| 17.02. | NovaBridge Biosciences: NovaBridge Doses First Patient in Global, Randomized Phase 2 Study of Givastomig Combined with Immunochemotherapy in Patients with 1L Metastatic Gastric Cancer | 507 | GlobeNewswire (Europe) | Global, randomized Phase 2 study to evaluate the addition of givastomig, a CLDN18.2 x 4-1BB bispecific antibody (8 mg/kg and 12 mg/kg) to standard of care immunochemotherapy in patients with first... ► Artikel lesen | |
| 06.02. | NovaBridge Biosciences - 6-K, Report of foreign issuer | 4 | SEC Filings | ||
| 06.02. | NovaBridge Biosciences stock price target raised to $9 by H.C. Wainwright | 2 | Investing.com | ||
| 20.01. | NovaBridge Biosciences: NovaBridge Announces Open Market Purchases by Executive Chairman, Fu Wei | 7 | GlobeNewswire (USA) | ||
| 16.01. | NovaBridge Biosciences - 6-K, Report of foreign issuer | 3 | SEC Filings |
1 2 3 Weiter >>
57 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 81,40 | -0,06 % | BioNTech vs. Bioxyne: Wenn Forschungs-Riesen pausieren und Small Caps die Prognosen anheben | ||
| EVOTEC | 4,530 | +0,09 % | Aktien KW 15 Trump hält die Börsen im Griff. Wacklige Waffenruhe bringt Erholung, aber… News. Mutares. Evotec. TKMS. technotrans. HENSOLDT. Renk. Circus. Albis Leasing. Rheinmetall | Aktien - Erholungsaufatmer nach Waffenstillstand. Mit apokalyptischen Drohungen malte Trump die "Steinzeit" für den Iran an die Wand. Unter Vermittlung Pakistans - auch Chinas? - gab es kurz vorher... ► Artikel lesen | |
| MEDIGENE | 0,025 | -18,83 % | Medigene: Zurückziehung - 18.11.2025 | ||
| QIAGEN | 35,045 | +0,04 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| MODERNA | 43,330 | -0,30 % | Moderna, Inc.: Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026 | CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present late-breaking oral presentations on revaccination data for both mRNA-1010... ► Artikel lesen | |
| PAION | 0,051 | -19,84 % | XFRA MISTRADE ANTRAG IN ISIN DE000A3E5EG5 WURDE STATTGEGEBEN | Dem Mistrade-Antrag wurde stattgegeben. Folgende Geschaefte in der ISIN DE000A3E5EG5, Wertpapier-Name: PAION AG INH O.N., wurden aufgehoben:ISIN Datum Zeit Volumen PreisDE000A3E5EG5 02.02.2026 08:13:40 300 0... ► Artikel lesen | |
| VALNEVA | 2,668 | -1,11 % | Valneva mit Rekordsignal: Was große Adressen zum Wochenstart bereits wissen - Was erfahrene Anleger jetzt analysieren | ||
| AMGEN | 299,00 | -0,10 % | Amgen: Phase 3 Trial Of TEPEZZA Meets Primary And Key Secondary Endpoints | THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) announced positive topline results from a Phase 3 trial of TEPEZZA administered by subcutaneous injection via an on-body injector in participants with... ► Artikel lesen | |
| NOVAVAX | 6,860 | -1,01 % | Activist investor revives campaign to overhaul Novavax board | ||
| STRYKER | 289,50 | +0,10 % | Stryker confident of 2026 outlook despite Q1 impact from cyberattack | ||
| BIOGEN | 147,04 | -0,28 % | Biogen to acquire Apellis in $5.6bn deal | ||
| BIOFRONTERA | 2,610 | +2,35 % | BIOFRONTERA AG im Abwärtsmodus - ruhige Einordnung | ||
| HEIDELBERG PHARMA | 2,810 | +3,31 % | EQS-Adhoc: Heidelberg Pharma AG: Heidelberg Pharma legt Dosis für Phase II-Studie (RP2D) mit dem ADC-Kandidaten HDP-101 fest | EQS-Ad-hoc: Heidelberg Pharma AG / Schlagwort(e): Sonstiges
Heidelberg Pharma AG: Heidelberg Pharma legt Dosis für Phase II-Studie (RP2D) mit dem ADC-Kandidaten HDP-101 fest
09.04.2026... ► Artikel lesen | |
| ILLUMINA | 102,88 | -0,23 % | Illumina Expands Collaboration With Labcorp To Advance Precision Oncology | SAN DIEGO (dpa-AFX) - Illumina, Inc. (ILMN), Wednesday announced an expanded collaboration with Labcorp to advance precision oncology through innovative applications of next-generation sequencing... ► Artikel lesen | |
| IMMUNOVANT | 24,500 | -4,48 % | IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints |
NOVABRIDGE BIOSCIENCES ADR gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +2,97 % bei einem Aktienkurs von 2,080 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NOVABRIDGE BIOSCIENCES ADR finden Sie auf Wallstreet Online.